The trade name of Merova, its generic name is rituximab, its onset of action for the treatment of thrombocytopenia varies from patient to patient, the response is mostly delayed, and it usually takes effect 4 to 8 weeks after the first injection. Rituximab is a second-line treatment for immune thrombocytopenia and is a good second-line treatment for relapsed or chronic ITP. Patients need to be infused once a week for four weeks. It aims to stop the cloning of plasma cells that make anti-platelet antibodies. Rituximab Hua, although very effective, has some side effects such as allergic reactions, infusion reactions, hepatitis B reactivation, progressive multifocal hereditary leukoencephalopathy and pulmonary toxicity. Patients are advised to use the drug under the guidance of a specialist to minimize adverse reactions.